Abstract:The EGFR family play a significant role in cell signal transduction and their overexpression is implicated in the pathogenesis of numerous human solid cancers. Inhibition of the EGFR-mediated signaling pathways by EGFR inhibitors is a widely used strategy for the treatment of cancers. In most cases, the EGFR inhibitors used in clinic were only effective when the cancer cells harbored specific activating EGFR mutations which appeared to preserve the ligand-dependency of receptor activation but altered the pattern of downstream signaling pathways. Moreover, cancer is a kind of multifactorial disease, and therefore manipulating a single target may result in treatment failure. Although drug combinations for the treatment of cancers proved to be successful, the use of two or more drugs concurrently still was a challenge in clinical therapy owing to various dose-limiting toxicities and drug-drug interactions caused by pharmacokinetic profiles changed. Therefore, a single drug targeting two or multiple targets could serve as an effective strategy for the treatment of cancers. In recent, drugs with diverse pharmacological effects have been shown to be more advantageous than combination therapies due to their lower incidences of side effects and more resilient therapies. Accordingly, dual target-single-agent strategy has become a popular field for cancer treatment, and researchers became more and more interest in the development of novel dual-target drugs in recent years. In this review, we briefly introduce the EGFR family proteins and synergisms between EGFR and other anticancer targets, and summarizes the development of potential dual target inhibitors based on wild-type and/or mutant EGFR for the treatment of solid cancers in the past five years. Additionally, the rational design and SARs of these dual target agents are also presented in detailed, which will lay a significant foundation for the further development of novel EGFR-based dual inhibitors with excellent druggability.

The Research Progress of New Targeted Therapy Drugs Lpatinib

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Lapatinib Resistance in HER2+ Cancers: Latest Findings and New Concepts on Molecular Mechanisms

Research Progress on Antitumor Mechanism of Apatinib

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)

A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer

Recent progress in targeted therapy for non-small cell lung cancer

Lapatinib for Breast Cancer′s Systematic Review and Metaanalysis

Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.

Clinical Application of Apatinib in the Treatment of Malignancies

The potential of lenvatinib in breast cancer therapy

Anlotinib As a Molecular Targeted Therapy for Tumors (Review)

Research Progress and Clinical Application of Targeting Medicines in the Treatment Against Non-Small Cell Lung Cancer

[Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer].

Lapatinib-incorporated Lipoprotein-Like Nanoparticles: Preparation and a Proposed Breast Cancer-Targeting Mechanism

Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics

The Efficacy and Safety of Apatinib in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Trial

1411P A Prospective, Multicenter, Real-World Study of Apatinib in the Treatment of Gastric Cancer

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)